Article

'Father of angiogenesis' to deliver keynote address at AAO opening session

San Francisco-Medical researcher Judah Folkman, MD, will headline the American Academy of Ophthalmology’s (AAO) opening session during the 2007 annual meeting, set for Nov. 10 to 13 in New Orleans.

San Francisco-Medical researcher Judah Folkman, MD, will headline the American Academy of Ophthalmology’s (AAO) opening session during the 2007 annual meeting, set for Nov. 10 to 13 in New Orleans.

“It is an honor to have such a distinguished and accomplished researcher kick off our annual meeting,” said H. Dunbar Hoskins Jr., MD, AAO executive vice president. “Dr. Folkman’s work has paved the way for numerous advances in cancer research and is helping those with age-related macular degeneration [AMD] have a chance to save and possibly regain some of their eyesight.”

Dr. Folkman, a 1953 graduate of Ohio State University and 1957 graduate of Harvard Medical School, is best recognized for his inroads in angiogenesis research. In 1971, he theorized in the New England Journal of Medicine that all tumor growth relies on angiogenesis. His research sparked continued scientific interest in the subject, which ultimately has resulted in novel approaches to the treatment of diseases such as cancer and AMD. Additionally, Dr. Folkman’s laboratory purified the first angiogenic tumor protein, found the first angiogenesis inhibitors, and pursued anti-angiogenic therapy-focused clinical trials.

He has written 389 original peer-reviewed papers and 106 book chapters and monographs; he holds honorary degrees from 15 universities and has received numerous national and international awards.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.